13therapeutics, Inc.

​​Our portfolio of patented novel anti-inflammatory peptides have application for the treatment of a variety of inflammatory diseases.  These anti-inflammatory therapeutics target individual intracellular signaling pathways of the Toll-Like Receptor (TLR) pathway.  Individual peptides have been identified which block either MyD88-Dependent or MyD88-Independent TLR signaling.  These peptides block the induction of multiple inflammatory mediators, such as TNF-alpha and IL-6, and have shown activity both in vitro and in preclinical inflammatory disease models.  

  • Peptide P13, and P13 derivative peptides, are inhibitors of multiple TLRs (TLR2, TLR4, and TLR9) and inhibit MyD88-Dependent TLR signaling 

  • Peptide P7, and P7 derivative peptides, are inhibitors of TLR3 and TLR4 and block MyD88-Independent TLR signaling